Incidence and Prognostic Impact of DNMT3A Mutations in Korean Normal Karyotype Acute Myeloid Leukemia Patients by 박상혁
Research Article
Incidence and Prognostic Impact of DNMT3A Mutations in
Korean Normal Karyotype Acute Myeloid Leukemia Patients
Sang Hyuk Park,1,2 Jae-Cheol Choi,3 Shine Young Kim,1,2 Jongyoun Yi,1,2
Seung Hwan Oh,4 In-Suk Kim,5 Hyung-Hoi Kim,1,2 Chulhun Ludgerus Chang,5
Eun Yup Lee,1,2 Moo-Kon Song,6 Ho-Jin Shin,6 and Joo Seop Chung6
1Department of Laboratory Medicine, Pusan National University School of Medicine, Pusan National University Hospital,
179 Gudeok-ro, Seo-gu, Busan 602-739, Republic of Korea
2Biomedical Research Institute, Pusan National University Hospital, 179 Gudeok-ro, Seo-gu, Busan 602-739, Republic of Korea
3Department of Laboratory Medicine, Hanmaeum Hospital, 21 Woni-daero, 682 Beon-gil, Seongsan-gu,
Changwon-si, Gyeongsangnam-do 642-832, Republic of Korea
4Department of Laboratory Medicine, Inje University College of Medicine, 75 Bokji-ro, Busanjin-gu, Busan 614-735, Republic of Korea
5Department of Laboratory Medicine, Pusan National University School of Medicine, Pusan National University Yangsan Hospital,
20 Geumo-ro, Mulgeum-eup, Yangsan-si, Gyeongsangnam-do 626-770, Republic of Korea
6Division of Hematology-Oncology, Department of Internal Medicine, Pusan National University School of Medicine,
Pusan National University Hospital, 179 Gudeok-ro, Seo-gu, Busan 602-739, Republic of Korea
Correspondence should be addressed to Eun Yup Lee; eylee@pusan.ac.kr
Received 10 October 2014; Revised 22 December 2014; Accepted 22 December 2014
Academic Editor: Martin Bornhaeuser
Copyright © 2015 Sang Hyuk Park et al.This is an open access article distributed under theCreative CommonsAttribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Background.DNAmethyltransferase 3A (DNMT3A)mutationwas recently introduced as a prognostic indicator in normal karyotype
(NK) AML and we evaluated the incidence and prognostic impact of DNMT3Amutations in Korean NK AML patients.Methods.
Total 67 NK AML patients diagnosed during the recent 10 years were enrolled. DNMT3A mutations were analyzed by direct
sequencing and categorized into nonsynonymous variations (NSV), deleterious mutations (DM), and R882 mutation based on
in silico analysis results. Clinical features and prognosis were compared with respect to DNMT3A mutation status. Results. Three
novel (I158M, K219V, and E177V) and two known (R736H and R882H) NSVs were identified and the latter three were predicted as
DMs. DNMT3A NSVs, DMs, and R882 mutation were identified in 14.9%–17.9%, 10.3%–10.4%, and 7.5% of patients, respectively.
DNMT3A mutations were frequently detected in FLT3 ITD mutated patients (P = 0.054, 0.071, and 0.071 in NSV, DMs, and R882
mutation, resp.) but did not affect clinical features and prognosis significantly. Conclusions. Incidences of DNMT3A NSVs, DMs,
and R882 mutation are 14.9%–17.9%, 10.3%–10.4%, and 7.5%, respectively, in Korean NK AML patients. DNMT3A mutations are
associated with FLT3 ITD mutations but do not affect clinical outcome significantly in Korean NK AML patients.
1. Introduction
Acute myeloid leukemia (AML) is a clonal hematologic
disorder exhibiting heterogeneous prognosis based on the
results of cytogenetic andmolecular aberration analysis [1, 2].
Among patients with AML, approximately half of them are
categorized into the intermediate prognosis group defined
in the recent National Comprehensive Cancer Network
(NCCN) guidelines [3]. In AML patients with intermediate
prognosis group, most of them show normal karyotype (NK)
and the prognosis of these patients generally depends on
molecular aberrations and fms-related tyrosine kinase 3 gene
internal tandem duplications (FLT3 ITD) which are detected
in 30% of AML patients and possess poor prognosis regard-
less of mutation status in other genes [4–8], nucleophosmin
(NPM1), and CCAAT/enhancer binding protein 𝛼 (CEBPA)
mutations which are detected in 50% and 13–15% of NK
AML, respectively, and exhibit good prognosis [9–15] having
been well established based on various previous studies. In
addition, the mutations in isocitrate dehydrogenase (IDH)1
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and 2 genes, which are identified in 6.0%–15.9% of AML
patients, were recently introduced as an unfavorable prognos-
tic indicator in NPM1mutated AML patients [16–19].
Besides these mutations described above, recent studies
based on the whole-genome sequencing approach found
a new prognostic marker of mutations in DNA methyl-
transferase 3A (DNMT3A) gene involving DNA methyla-
tion, which is the most important epigenetic process in
the regulation of gene expression and chromatin structural
remodeling, in the patients withNKAML [20–23].DNMT3A
mutations have been reported in 18–22% of AML (29–34%
of CN-AML) [24–27] and previous studies showed that the
mutations of DNMT3A in AML are frequently found in
the patients with NPM1 mutations and have the mutation
hotspot of arginine in 882th codon (R882) [20–27]. Some
previous studies reported that the patients with DNMT3A
mutations show inferior overall survival (OS) compared to
those without mutations [20, 21, 25] and another recent study
reported a trend of more frequent relapse and inferior OS
in the patients who achieved complete remission (CR) when
they possess DNMT3A mutations [27]. However, in contrast
toNPM1 andCEBPAmutations inwhich the prognostic value
was confirmed and which were included as a provisional
entity in the 2008 WHO classifications, the prognostic value
of DNMT3A mutations as well as IDH1/2 mutations has not
been confirmed up to present time. In addition, although two
recent studies reported poor prognostic impact of DNMT3A
mutations in Chinese and Taiwanese AML patients [28, 29],
studies which analyzed the clinical relevance of DNMT3A
mutations in Asian population are outnumbered compared
to Western population and there have been no reports on
the clinical impact of DNMT3A mutations in Korean AML
patients.
In this study, we performed direct sequencing of all 23
exons in DNMT3A gene in 39 NK AML patients who were
diagnosed at single tertiary hospital in Korea and analyzed
the mutation characteristics. In addition, we performed in
silico analysis to predict the deleterious effect of detected
nonsynonymous variations on the protein function and
structure and estimated the clinical relevance of DNMT3A
mutations on the prediction of clinical course while including
another 28 NK AML patients.
2. Materials and Methods
2.1. Patients Selection. A total of 60 NK AML patients who
were diagnosed from January 2004 to July 2010 and treated
in PusanNational University Hospital were initially recruited
from the retrospective review of electronic medical record
(EMR), and a total of 39 patients in whom the quality of
extracted bonemarrow (BM)DNAat diagnosis was sufficient
to be analyzed by direct sequencing were finally enrolled in
the first study cohort. In these 39 patients, direct sequencing
of all 23 exons in DNMT3A gene was performed to analyze
the incidence and distribution characteristics of all detected
variations in DNMT3A gene. The median age and follow-up
interval of first study cohort was 39.0 years (range: 11.0 years–
83.0 years) and 5.2 months (range: 0.0 months–72.0 months),
respectively, and this cohort included 25 male (64.1%) and 14
female (35.9%) patients.
In addition, total 28 NK AML patients who were diag-
nosed from August 2010 to March 2014 at the same hospital
were additionally enrolled as second study cohort to evaluate
the clinical and prognostic impact of mutation hotspot R882
in DNMT3A gene. In these patients, direct sequencing of
DNMT3A exon 23 was performed. The median age and
follow-up interval of second study cohort were 28.0 years
(range: 15.0 years–80.0 years) and 6.4 months (range: 0.1
months–42.6 months), respectively, and this cohort included
12 male (42.9%) and 16 female (57.1%) patients.
2.2. Patients Treatment. All these patients received induction
chemotherapy with cytarabine 100mg/m2/day for seven days
plus daunorubicin 45mg/m2/day for three days (the AD
regimen) or cytarabine 100mg/m2/day for seven days plus
idarubicin 12mg/m2/day for three days (the AI regimen).
CR was defined by less than 5% of residual leukemic blasts
in the BM aspirates and more than 20% of BM cellularity,
normal maturation of all cellular components (erythrocytic,
granulocytic, andmegakaryocytic series) in the BMaspirates,
normal values for absolute neutrophil counts (>1,000/𝜇L)
and platelet counts (>100,000/𝜇L) after the first or second
course of induction chemotherapy. Relapsewas defined as the
presence of ≥5% leukemic blasts in BM aspirates for patients
who had previously achieved CR. Stem cell transplantation
(SCT) after first CR achievement were considered as a
final treatment modality depending on the patient’s age,
availability of a suitable donor, and FLT3 ITDmutation status.
As a prognosis indicator, CR, relapse, and death rates
were used and both OS and event-free survival (EFS) were
additionally calculated. OS was defined as the interval from
diagnosis to death or last follow-up. EFS was defined as the
interval from CR to relapse or death for patients who were
relapsed or expired during follow-up or the interval from CR
to last follow-up for surviving patients who were not relapsed
during follow-up interval. If the patient underwent SCT, the
CR date was replaced by the SCT date in the calculation
of EFS. This study was approved by the institutional review
board of author’s institution.
2.3. Mutation Analysis of DNMT3A Gene. DNA samples
were extracted from the unstained remnant smear slides
of BM aspirates or chromosomal cell pellets obtained at
diagnosis using DNA Blood Mini extraction kit (Qiagen,
Hilden, Germany), as recommended by manufacturer. All 23
exons of DNMT3A gene were amplified with primers listed
in Table 1. All forward and reverse primers hadM13F binding
tag (tgtaaaacgacggccagt) andM13Rbinding tag (caggaaacagc-
tatgacc) on the 5󸀠 ends of each primer. Polymerase chain
reactions (PCR) were conducted with hot start procedure
according to the manufacturer’s instructions (i-StarTaq,
INTRON Biotechnology, Sungnam, Korea) described below:
an initial denaturation at 95∘C for 5 minutes and by 30 cycles
of following denaturation at 95∘C for 30 seconds, annealing
at 60∘C for 30 seconds, and extension at 72∘C for 30 seconds.
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Table 1: The forward and reverse primer sequences used in the amplification of all 23 exons in DNMT3A gene.
Primer Primer sequence
>DNMT02F tgtaaaacgacggccagtTCCAAAGACCACGATAATTCCTTC
>DNMT03F tgtaaaacgacggccagtCTGGAATGCTACACTGCTGGG
>DNMT04F tgtaaaacgacggccagtACTTGGAGAAGCGGAGTGAGC
>DNMT05F tgtaaaacgacggccagtGGATGTGTAAAGAAGGAGGAGGG
>DNMT06F tgtaaaacgacggccagtACATTGTGTTTGAGGCGAGTGC
>DNMT07F tgtaaaacgacggccagtCTAATTCCTGGAGAGGTCAAGGTG
>DNMT08F tgtaaaacgacggccagtTCTTGCCTCATTCAGATGGAGC
>DNMT09F tgtaaaacgacggccagtGTGCTTGCAAGTGTAAGCCTCG
>DNMT10F tgtaaaacgacggccagtCTTGAGCCTGACCCATCTGC
>DNMT11F tgtaaaacgacggccagtTTCCTGTCAGCCTGTAACTGACC
>DNMT12F tgtaaaacgacggccagtTTATTGATGAGCGCACAAGAGG
>DNMT13F tgtaaaacgacggccagtAGGGAGAGGCCCTTCGGTGG
>DNMT14F tgtaaaacgacggccagtGGTCATGTCTTCAGGGCTTAGG
>DNMT15F tgtaaaacgacggccagtTTTCCATTCCAGGTAGCACACC
>DNMT16F tgtaaaacgacggccagtAGGGTGTGTGGGTCTAGGAGC
>DNMT17F tgtaaaacgacggccagtGACTTGGGCCTACAGCTGACC
>DNMT18F tgtaaaacgacggccagtATAGGACAGTGGTGTGGCTCG
>DNMT19F tgtaaaacgacggccagtGACAGCTATTCCCGATGACCC
>DNMT20F tgtaaaacgacggccagtGCCGGCGCTGTTTCATGC
>DNMT21F tgtaaaacgacggccagtCCTTCCCGCTGTTATCCAGG
>DNMT22F tgtaaaacgacggccagtTGGCATATTTGGTAGACGCATGAC
>DNMT23F tgtaaaacgacggccagtTCCCAGTCCACTATACTGACGTCTC
>DNMT91F tgtaaaacgacggccagtACAAAGAAAATGTTCCCTCCCTCC
>DNMT92F tgtaaaacgacggccagtAAATCTGGTATGGTGGAAATGGG
>DNMT02R caggaaacagctatgaccTCCCTCTCCCAGGCCAGA
>DNMT03R caggaaacagctatgaccATACATCACTGCCATCGACAGG
>DNMT04R caggaaacagctatgaccAAGCAGACCTTTAGCCACGACC
>DNMT05R caggaaacagctatgaccGAACAGCTAAACGGCCAGAGG
>DNMT06R caggaaacagctatgaccACTGAGGCCCATCACTTCTGG
>DNMT07R caggaaacagctatgaccAGATGGAGAGAGGAGAGCAGGAC
>DNMT08R caggaaacagctatgaccCCTGGGATCAAGAACCTTCCC
>DNMT09R caggaaacagctatgaccCCTGCACTCCAACTTCCAGG
>DNMT10R caggaaacagctatgaccGCAGGTCATTCAAGTCCTGACC
>DNMT11R caggaaacagctatgaccATGCAGGCCTCCTGGTGC
>DNMT12R caggaaacagctatgaccTCCCATGTCATTCAAACCTTCC
>DNMT13R caggaaacagctatgaccACACAGTCAGCCAGAAGGCCG
>DNMT14R caggaaacagctatgaccTGCTACCTGGAATGGAAAGACC
>DNMT15R caggaaacagctatgaccAGGCTCCTAGACCCACACACC
>DNMT16R caggaaacagctatgaccGCTGTGAAGCTAACCATCATTTCG
>DNMT17R caggaaacagctatgaccAAATGAAAGGAGGCAAGGGC
>DNMT18R caggaaacagctatgaccTTCTTCCTGTCTGCCTCTGTCC
>DNMT19R caggaaacagctatgaccTGCAGATGAGACAGGATGAAGC
>DNMT20R caggaaacagctatgaccCCACTATGGGTCATCCCACCTGC
>DNMT21R caggaaacagctatgaccCATCCTGCCCTTCCTTCTCC
>DNMT22R caggaaacagctatgaccTGGGAAATGCTTGATAAAACCCAC
>DNMT23R caggaaacagctatgaccTCTCTCCATCCTCATGTTCTTGG
>DNMT91R caggaaacagctatgaccCCAGCACTAAGTCAGCATCTCCAG
>DNMT92R caggaaacagctatgaccTGGAGTTCTTATGGATCACACCC
DNMT3A: DNA methyltransferase 3A; F: forward; R: reverse.
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A final extension was done at 72∘C at 5 minutes on Verity-
96 well thermal cycler PCR system (Applied Biosystems Inc.,
Foster City, CA, USA).
PCR products were purified with AccuPrep kit (Bioneer,
Daejeon, Korea) and were used in the sequencing reaction
using BigDye Terminator v.3.1 Cycle Sequencing Ready Reac-
tion kit (Applied Biosystems Inc., USA). Direct sequencing of
all 23 exons was performed with ABI 3130 Genetic Analyzer
(Applied Biosystems Inc., USA). The SeqScape software
version 2.6 (Applied Biosystems Inc., USA) was used to align
the obtained and reference sequences (NM 175629.2) and all
detected nonsynonymous and synonymous variations were
described according to the guidelines of the Human Gene
Variation Society (HGVS; http://www.hgvs.org/).
2.4. In Silico Analysis to Predict the Deleterious Effect of All
Detected Nonsynonymous Variations on the Protein Function
and Structure. To predict the deleterious effect of novel and
known sequence variations, all detected nonsynonymous
variations were submitted to three web-based programs:
Sorting Intolerant From Tolerent (SIFT, http://sift.jcvi.org/),
Polyphen-2 (version 2.2.2, http://genetics.bwh.harvard.edu/
pph/), and MutationTaster (http://www.mutationtaster
.org/).Theweb-based database dbSNP (http://www.ncbi.nlm
.nih.gov/projects/SNP/) was applied in the confirmation of
known SNP and the novelty of detected nonsynonymous
variations was validated by web-based database Catalogue
of Somatic Mutations in Cancer (COSMIC, http://cancer
.sanger.ac.uk/cancergenome/projects/cosmic/). Cn3D mac-
romolecular structure viewer was used to annotate the
mutation sites in 3D structure [30].
2.5. Comparison of Clinical Characteristics and Prognosis in
Patientswith respect toMutation Status ofDNMT3AGene. To
assess the clinical relevance of DNMT3A mutation analysis,
the comparison of clinical characteristics and prognosis
in NK AML patients with respect to mutation status of
DNMT3A geneswas performed.All patientswere categorized
into two subgroups with respect to nonsynonymous variation
status of DNMT3A gene and both clinical features and prog-
nosis were compared between two subgroups to evaluate the
clinical relevance of nonsynonymous variations of DNMT3A
gene. Subsequently, nonsynonymous variations which were
predicted as deleterious mutation in at least two of three in
silico analyses were recruited and identical comparisons were
performed again between patients with deleteriousmutations
and those without deleterious mutations to further evaluate
the clinical relevance of deleterious mutations in DNMT3A
gene.
Finally, to evaluate the clinical relevance of DNMT3A
R882mutation hotspot, all patients were categorized into two
subgroups with respect to DNMT3A R882 mutation status,
and identical comparisons were performed again. Clinical
data of patients were obtained from retrospective review
of EMR and included age and gender, complete blood cell
(CBC) counts, blasts (%) in BMaspirates, FLT3 ITD andD835
mutation status (at diagnosis), and date of CR, relapse, and
death (during follow-up).
2.6. Multivariate Analysis of Overall Survival. For the iden-
tification of prognostic impact in DNMT3A mutations in
association with other possible prognostic indicators such
as FLT3 ITD mutation status, age, BM blast (%), and SCT
performance status, the multivariate analysis was performed
when the clinical variablesmentioned above were included as
covariables.
2.7. Statistical Analysis. Pearson chi-square yest or Fisher’s
exact test (for small numbers less than 5) were applied to
compare categorical variables (gender, CR rates, relapse rates,
and death rates) between each two patient subgroups. Mann-
Whitney 𝑈 test was used to compare continuous variables
(age, CBC counts at diagnosis and interval from diagnosis to
CR) between each two patient subgroups. Estimates of OS
and EFS were generated using Kaplan-Meier methods and
were compared using a log-rank test. Multivariate analyses
of OS were performed with a Cox’s proportional hazards
model. For all analyses, tests were two-tailed and 𝑃 values ≤
0.05 and 0.05–0.10 were considered statistically significant
and marginally significant, respectively. All calculations were
performed using SPSS 13.0.1 forWindows (SPSS Inc, Chicago,
IL, USA).
3. Results
3.1. Summary of Detected Variations in DNMT3A Gene.
Among 39 patients included in the first study cohort, two
known synonymous variations (c.27C>T (rs41284843, minor
allele frequency = 0.0851) and c.1266G>A (rs2276598, minor
allele frequency = 0.2337)) and one novel synonymous
variation (c.2043C>G) were detected in 5, 19 (including 2
homozygotes), and 6 patients (12.8%, 48.7%, and 15.4%),
respectively.
Total five different nonsynonymous variations, which
are all missense mutations, were detected in seven (17.9%)
patients and included two known mutations (c.2207G>A
(p.Arg736His, COSM133737, detected in one patient) and
c.2645G>A (p.Arg882His, COSM52946, detected in two
patients)) and three novelmutations (c.474C>G(p.Ile158Met,
detected in two patients), c.530A>T (p.Glu177Val, detected
in one patient), and c.656A>G (p.Lys219Arg, detected in two
patients)). All 7 patients with DNMT3A mutations harbored
single mutation, except for one patient who showed both
K219R and R736H mutations simultaneously. All 2 known
mutations (R736HandR882H) induced protein change in the
catalytic domain of DNMT3A protein which has critical role
in methyltransferase activity, and all three novel mutations
(I158M, E177V, and K219R) were involved in protein change
at the regulatory domain of DNMT3A protein. These results
are summarized in Figure 1.
Subsequently performed direct sequencing of DNMT3A
exon 23 in 28 NKAML patients who were included in second
study cohort detected additional three R882H mutations.
When summarizing these results, the incidence of DNMT3A
nonsynonymous variations was calculated to be 7/39 (17.9%)
in the first study cohort and finally estimated to be 10/67
(14.9%) when adding data from 28 patients in the second
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Figure 1: Electropherograms of all DNMT3A variations including synonymous and nonsynonymous variations observed in this study (a)
and schematic summary representing locations and frequency of all detected DNMT3A variations (b). Note: (a) shows electropherogram of
all detected DNMT3A variations in 39 patients included in the first study cohort. (b) shows schematic summary of all detected DNMT3A
variation including location and frequency. The number of circles indicates the frequency of detected variations. Closed black and white
circle indicates heterozygous nonsynonymous and synonymous variation case, respectively, and closed double-layered white circle indicates
homozygous synonymous variation case. Abbreviations: P, proline; I, isoleucine; M, methionine; R, arginine; H, histidine; L, leucine; E,
glutamate; V, valine; K, lysine; PWWP, Pro-Trp-Trp-Pro motif; ZNF, zinc finger; MeTFase, methyltransferase.
study cohort, and the frequency ofDNMT3AR882mutations
was exactly calculated to be 5/67 (7.5%).
3.2. In Silico Analysis Results to Predict the Deleterious Effect
of Detected Nonsynonymous Variations on the Protein Func-
tion and Structure. Among five DNMT3A nonsynonymous
variations detected in this study, R882H was predicted as
a deleterious mutation by all three web-based prediction
programs, as reported in the previous study [21] and another
known variation (R736H) was also predicted as a deleterious
mutation by two programs. In addition, one novel variation
(E177V) was also predicted as a deleterious mutation by all
three programs. In contrast, two novel variations (I158M and
K219R) were predicted as a benign or tolerated variation in
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Table 2: In silico analysis results of three web-based programs to predict the deleterious effect of detected nonsynonymous variations on the
protein function and structure.
Mutations Sequence variationdatabase
SIFT Polyphen-2 MutationTaster
Score Prediction Score Prediction Score Prediction
I158M Novel 0.21 Tolerated 0.191 Benign 0.27 Polymorphism
E177V Novel 0.02 Damaging 0.981 Probably damaging 3.30 Disease causing
K219R Novel 0.71 Tolerated 0.002 Benign 0.71 Polymorphism
R736H rs139293773COSM133737 0.39 Tolerated 0.997 Probably damaging 0.79 Disease causing
R882H rs147001633COSM52946 0.03 Damaging 0.651 Possibly damaging 0.79 Disease causing
I: isoleucine; M: methionine; E: glutamate; V: valine; K: lysine; R: arginine; H: histidine.
all three programs. These results are represented in Table 2.
With these results, the frequency of deleterious mutation of
DNMT3A gene was calculated to be 4/39 (10.3%) in the first
study cohort and finally estimated to be 7/67 (10.4%) when
adding data from 28 patients in the second study cohort.
In the 3D structure model of methyltransferase domains,
R882 residue was located in the region interfacing with two
DNMT3A molecules, which is consistent with the results of
previous literature [21], and R736 residue was located on the
opposite side and toward DNMT3L molecule. These results
are illustrated in the Supplemental Figure 1 available online
at http://dx.doi.org/10.1155/2015/723682.
3.3. Comparison of Clinical Characteristics and Prognosis in
Patients with respect toMutation Status of DNMT3AGene. In
the comparison of patients with DNMT3A nonsynonymous
variations and those without nonsynonymous variations,
both clinical features and prognosis (OS and EFS) were
not significantly different between two patient subgroups,
except for the trend of high FLT3 ITD mutation frequency
in patients with DNMT3A nonsynonymous variations than
those who do not harbor (66.7% versus 24.4%, 𝑃 = 0.054).
Identical results were found in the comparison with respect
to DNMT3A deleterious mutation status, since the patients
with DNMT3A deleterious mutations also showed the trend
of more frequent FLT3 ITD mutation than those without
DNMT3A deleterious mutations (75.0% versus 25.5%, 𝑃 =
0.071). Additionally performed comparison between patients
with DNMT3A R882 mutation and those without R882
mutation also showed identical results again.These results are
summarized in Table 3 and Figure 2.
3.4. Multivariate Analysis of Overall Survival. Themultivari-
ate analysis of OS in total 67 NK AML patients demonstrated
that the presence of FLT3 ITD mutation is a significantly
poor prognostic indicator of OS (hazard ratio 2.798, 𝑃 =
0.041) and the performance of SCT during follow-up is
a significantly good prognostic indicator of OS (hazard ratio
0.118, 𝑃 = 0.001) as expected. However, the presence of
DNMT3A nonsynonymous variations (hazard ratio 1.229,
𝑃 = 0.724), deleterious mutations, and R882 mutations
(hazard ratio 2.285, 𝑃 = 0.313 in both) did not affect OS
significantly as well as increasing age and BM blasts (%),
although the trend was toward to adverse prognosis. These
results are described in Table 4.
4. Discussion
Previous studies that analyzed DNMT3A mutations showed
that the incidence of DNMT3A mutation is 18–22% of AML
and 29–34% of NK AML [24–27], including the largest
study which analyzed 489 AML patients and reported the
frequency of DNMT3A mutation as 17.8% of AML patients
and 27.2% of NK AML patients [24]. In Korean population,
although the data of clinical outcome was not provided,
a recent study reported the incidence of DNMT3A R882
mutation as 9.4% in adulthood AML [31]. Our present study
showed that the incidence of DNMT3A nonsynonymous
variations is 17.9% in first study cohort and 14.9% in extended
cohort, which is similar to the results from previous studies
[24–27]. In addition, our present study analyzed the inci-
dence of DNMT3A R882 mutation as 7.5%, which is also
similar to the previous data in Korean population [31]. All
these results demonstrate thatDNMT3Amutation can be also
considered as a frequently occurring nonrandommutation in
Korean NK AML patients.
Our present study applied direct sequencing of all 23
exons in DNMT3A gene to identify all possible variations
affectingDNMT3A protein function and structure and could
detect total 8 different sequence variations, including 3
synonymous and 5 nonsynonymous variations. Among three
synonymous variations, two known variations (c.27C>T and
c.1266G>A) of which minor allele frequencies are 8.51% and
23.37% were found with the frequency of 12.8% and 48.7%,
respectively, and therefore these two variations can be con-
sidered as constitutional single nucleotide polymorphisms
(SNP). In addition, our present study could detect one novel
synonymous variation (c.2043C>G), with the incidence of
15.4% and this novel SNP can be listed in the current SNP
databases.
For the nonsynonymous variations, we could find 3
different novel variations (I158M, E177V, and K219V) in the
regulatory domains of DNMT3A protein that have a role
in interaction with other molecules and protein localization
to the nuclei, as well as 2 known variations (R736H and
R882) located in the catalytic methyltransferase domain of
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Figure 2: Comparisons of overall survival and event-free survival in total 67 NK AML patients with respect to DNMT3A nonsynonymous
variations ((a) and (d)), deleterious mutations ((b) and (e)), and R882 mutation ((c) and (f)), respectively. Abbreviation: R, arginine.
DNMT3A protein. In addition, in silico analysis performed
in our study predicted not only both R736H and R882H vari-
ations in catalytic domain but also a novel E177V variation in
regulatory domain to be deleterious to protein function, and
previously known mutation hotspot R882 was not frequently
detected in our present study. These results can be novel
findings of our present study since R882 residue ofDNMT3A
gene has been regarded as a frequently mutated hotspot in
previous studies [20, 21, 24–27], which would have a gain-
of-function activity or dominant negative effects [20]. All
these results may suggest the presence of ethnic variation
in the characteristics of DNMT3A mutations and justify the
application of detection method which covers all exons of
DNMT3A gene rather thanmutation hotspot R882 in Korean
population.
Our structural analysis using 3D model showed that
R736 residue is exposed to the DNMT3L molecules that
are a stimulating factor of DNMT3A and a mediator of
transcriptional repression through interaction with histone
deacetylase 1 [30]. Therefore, it may be considered that
the alteration of R736 residue may affect the efficiency and
regulation of DNMT3A protein function, as similarly with
previously demonstrated R882 residue [21]. In contrast, in
the regulatory domain of DNMT3A protein, only E177V was
identified as deleterious mutation and we could not provide
the possible explanation for this result in our present study.
More extensive functional analysis on the DNMT3A protein
should be required for the clarification of this finding.
DNMT3A mutations have been reported to occur in
patients with NPM1 and FLT3 mutations [24, 25, 27] but
the clinical and prognostic impact of DNMT3A mutations
has not been confirmed yet. Some studies revealed the
poor prognostic effect of DNMT3A mutations on survival
outcome, both in overall [25] and in high risk (FLT3 ITD
mutated but NPM1 nonmutated) NK AML patients [24].
Two studies performed in Asian population also reported
poor prognostic impact of DNMT3Amutations in NK AML
[28, 29]. In contrast, other studies also reported no significant
prognostic effect of DNMT3A mutations in AML patients
with intermediate risk group [27] and in low risk (NPM1
mutated but FLT3 ITD unmutated) NK AML patients [24].
A recent study reported that the poor prognostic relevance
BioMed Research International 9
Table 4: Multivariate analysis of overall survival.
Variables Overall survival
HR (95% CI) 𝑃 value Prognostic impact
All 67 patients
FLT3 ITD mutation (compared with wild type) 2.798 (1.041–7.517) 0.041 Poor
DNMT3Amutation (compared with wild type)
Nonsynonymous variations 1.229 (0.391–3.864) 0.724 NS∗
Deleterious mutations 2.285 (0.459–11.374) 0.313 NS∗
R882 mutation 2.285 (0.459–11.374) 0.313 NS∗
Increasing age 1.023 (0.991–1.055) 0.157 NS
Increrasing BM blasts 1.018 (0.986–1.051) 0.285 NS
SCT performed (compared to not performed) 0.118 (0.035–0.399) 0.001 Good
Note: 𝑃 values were adjusted with FLT3 ITD mutation status, age, BM blast percentage, and stem cell transplantation performance status (in all 67 patients∗).
FLT3: fms-related tyrosine kinase 3; ITD: internal tandem duplications; DNMT3A: DNAmethyltransferase 3A; R: arginine; BM: bone marrow; SCT: stem cell
transplantation; HR: hazard ratio; CI: confidence interval; NS: not significant.
of DNMT3A mutation is dependent on age and its mutation
type (R882 versus non-R882) [26]. Our present study could
also demonstrate a trend of association between FLT3 ITD
mutation and DNMT3A mutations in terms of mutation
frequency, as reported in the previous literature [24, 25, 27].
However, our present study could not demonstrate a signif-
icant effect of DNMT3A mutations on both clinical features
and prognosis, regardless of mutation type (nonsynonymous
variations, deleterious mutations, or R882 mutation hotspot)
in Korean NK AML patients although the trend was toward
adverse prognosis. This result may support previously given
hypothesis in our present study referring the presence of
ethnic variation in the characteristics ofDNMT3Amutations.
In addition, from our present study result it can be speculated
that the adverse prognostic effect ofDNMT3Amutationsmay
not exist in overall Korean NK AML patients and although
some variations are predicted to be deleterious to protein
function in our study, the adverse prognostic impact may
reside in all non-synonymous variations of DNMT3A gene
and, therefore, all 23 exons of DNMT3A gene should be
screened for the detection of clinically important DNMT3A
mutations.
Our study has some important limitations in terms of
small patient numbers in each subgroup and mutation anal-
ysis of other genes with clinical significance. First, our study
cohort included total 67 patients (39 in first and 28 in second
study cohort) who were diagnosed and treated in single
tertiary hospital, and statistical power in the comparison
of clinical features and prognosis with respect to DNMT3A
mutation status, especially in the analysis focused on FLT3
ITD mutated patients, is estimated to be significantly low.
Therefore, our present results should be interpreted with
caution and regarded to be preliminary data providing future
issues to be addressed. Second, although both NPM1 and
CEBPA mutations have prognostic value in NK AML and
some previous study also suggested the association of NPM1
and DNMT3A mutations [24, 25, 27], our present study
did not include the data of NPM1 and CEBPA mutation
status and, therefore, comprehensive analysis in terms of
mutational relations among three genes (NPM1, CEBPA, and
DNMT3A) could not be performed. More large scaled and
comprehensive study with these data should be required in
the future to address these points.
5. Conclusions
Our present study identified three novel (I158M, E177V, and
K219V in the regulatory domain) and two known (R736Hand
R882H in the methyltransferase domain) DNMT3A nonsyn-
onymous variations, and three (E177V, R736H and R882H)
of them were predicted to be deleterious to protein function
and structure. The incidences of DNMT3A nonsynonymous
variations, deleterious mutations, and R882 mutation were
14.9%–17.9%, 10.3%–10.4%, and 7.5%, respectively, in Korean
NKAMLpatients, without predominance of knownmutation
hotspot R882. DNMT3Amutations were frequently detected
in FLT3 ITD mutated NK AML patients but did not signif-
icantly affect clinical features and prognosis in Korean NK
AML patients, and this issue needs to be further evaluated
in the future.
Conflict of Interests
The authors declare that there is no conflict of interests
regarding the publication of this paper.
Acknowledgments
This study was supported by Biomedical Research Institute
and Pusan Cancer Center Grant (2011-30), Pusan National
University Hospital.
References
[1] J. C. Byrd, K. Mro´zek, R. K. Dodge et al., “Pretreatment
cytogenetic abnormalities are predictive of induction success,
cumulative incidence of relapse, and overall survival in adult
patients with de novo acute myeloid leukemia: results from
cancer and leukemia group B (CALGB 8461),” Blood, vol. 100,
no. 13, pp. 4325–4336, 2002.
[2] D. Grimwade, H. Walker, F. Oliver et al., “The importance
of diagnostic cytogenetics on outcome in AML: analysis of
10 BioMed Research International
1,612 patients entered into the MRC AML 10 trial. The Medical
Research Council Adult and Children’s Leukaemia Working
Parties,” Blood, vol. 92, pp. 2322–2333, 1998.
[3] M. R. O’Donnell, C. N. Abboud, J. Altman et al., “Acute myeloid
leukemia,” Journal of the National Comprehensive Cancer Net-
work, vol. 10, no. 8, pp. 984–1021, 2012.
[4] S. P. Whitman, K. J. Archer, L. Feng et al., “Absence of the
wild-type allele predicts poor prognosis in adult de novo acute
myeloid leukemia with normal cytogenetics and the internal
tandem duplication of FLT3: a cancer and leukemia group B
study,” Cancer Research, vol. 61, no. 19, pp. 7233–7239, 2001.
[5] Y. Yamamoto, H. Kiyoi, Y. Nakano et al., “Activatingmutation of
D835 within the activation loop of FLT3 in human hematologic
malignancies,” Blood, vol. 97, no. 8, pp. 2434–2439, 2001.
[6] B. Kainz, D. Heintel, R. Marculescu et al., “Variable prognostic
value of FLT3 internal tandem duplications in patients with de
novo AML and a normal karyotype, t(15;17), t(8;21) or inv(16),”
The Hematology Journal, vol. 3, no. 6, pp. 283–289, 2002.
[7] S. P. Whitman, K. Maharry, M. D. Radmacher et al., “FLT3
internal tandem duplication associates with adverse outcome
and gene- and microRNA-expression signatures in patients 60
years of age or older with primary cytogenetically normal acute
myeloid leukemia: a cancer and leukemia group B study,” Blood,
vol. 116, no. 18, pp. 3622–3626, 2010.
[8] S. P. Whitman, A. S. Ruppert, M. D. Radmacher et al., “FLT3
D835/I836 mutations are associated with poor disease-free sur-
vival and a distinct gene-expression signature among younger
adults with de novo cytogenetically normal acute myeloid
leukemia lacking FLT3 internal tandem duplications,” Blood,
vol. 111, no. 3, pp. 1552–1559, 2008.
[9] S. Schnittger, C. Schoch, W. Kern et al., “Nucleophosmin
gene mutations are predictors of favorable prognosis in acute
myelogenous leukemia with a normal karyotype,” Blood, vol.
106, no. 12, pp. 3733–3739, 2005.
[10] K. Do¨hner, R. F. Schlenk, M. Habdank et al., “Mutant nucle-
ophosmin (NPM1) predicts favorable prognosis in younger
adults with acute myeloid leukemia and normal cytogenetics:
interaction with other gene mutations,” Blood, vol. 106, no. 12,
pp. 3740–3746, 2005.
[11] R. G. W. Verhaak, C. S. Goudswaard, W. van Putten et
al., “Mutations in nucleophosmin (NPM1) in acute myeloid
leukemia (AML): association with other gene abnormalities
and previously established gene expression signatures and their
favorable prognostic significance,” Blood, vol. 106, no. 12, pp.
3747–3754, 2005.
[12] S. Fro¨hling, R. F. Schlenk, I. Stolze et al., “CEBPA mutations
in younger adults with acute myeloid leukemia and normal
cytogenetics: prognostic relevance and analysis of cooperating
mutations,” Journal of Clinical Oncology, vol. 22, no. 4, pp. 624–
633, 2004.
[13] C. L. Green, K. K. Koo, R. K. Hills, A. K. Burnett, D. C.
Linch, and R. E. Gale, “Prognostic significance of CEBPA
mutations in a large cohort of younger adult patients with acute
myeloid leukemia: impact of double CEBPAmutations and the
interaction with FLT3 andNPM1mutations,” Journal of Clinical
Oncology, vol. 28, no. 16, pp. 2739–2747, 2010.
[14] C. Preudhomme, C. Sagot, N. Boissel et al., “Favorable prog-
nostic significance of CEBPA mutations in patients with de
novo acutemyeloid leukemia: a study from the Acute Leukemia
French Association (ALFA),” Blood, vol. 100, no. 8, pp. 2717–
2723, 2002.
[15] S. H. Park, H. S. Chi, Y. U. Cho, S. Jang, and C. J. Park, “CEBPA
single mutation can be a possible favorable prognostic indicator
in NPM1 and FLT3-ITD wild-type acute myeloid leukemia
patientswith intermediate cytogenetic risk,”LeukemiaResearch,
vol. 37, no. 11, pp. 1488–1494, 2013.
[16] S. Abbas, S. Lugthart, F. G. Kavelaars et al., “Acquiredmutations
in the genes encoding IDH1 and IDH2 both are recurrent aber-
rations in acute myeloid leukemia: prevalence and prognostic
value,” Blood, vol. 116, no. 12, pp. 2122–2126, 2010.
[17] P. Paschka, R. F. Schlenk, V. I. Gaidzik et al., “IDH1 and IDH2
mutations are frequent genetic alterations in acute myeloid
leukemia and confer adverse prognosis in cytogenetically nor-
mal acutemyeloid leukemiawithNPM1mutationwithout FLT3
internal tandem duplication,” Journal of Clinical Oncology, vol.
28, no. 22, pp. 3636–3643, 2010.
[18] H.-Y. Chao, Z.-X. Jia, T. Chen et al., “IDH2 mutations are
frequent in Chinese patients with acute myeloid leukemia
and associated with NPM1 mutations and FAB-M2 subtype,”
International Journal of Laboratory Hematology, vol. 34, no. 5,
pp. 502–509, 2012.
[19] F. Ravandi, K. Patel, R. Luthra et al., “Prognostic significance
of alterations in IDH enzyme isoforms in patients with AML
treated with high-dose cytarabine and idarubicin,” Cancer, vol.
118, no. 10, pp. 2665–2673, 2012.
[20] T. J. Ley, L. Ding, M. J. Walter et al., “DNMT3A mutations in
acute myeloid leukemia,”TheNew England Journal of Medicine,
vol. 363, no. 25, pp. 2424–2433, 2010.
[21] X.-J. Yan, J. Xu, Z.-H. Gu et al., “Exome sequencing identifies
somatic mutations of DNA methyltransferase gene DNMT3A
in acute monocytic leukemia,” Nature Genetics, vol. 43, no. 4,
pp. 309–315, 2011.
[22] M. A. McDevitt, “Clinical applications of epigenetic markers
and epigenetic profiling in myeloid malignancies,” Seminars in
Oncology, vol. 39, no. 1, pp. 109–122, 2012.
[23] J. J. Trowbridge, J. W. Snow, J. Kim, and S. H. Orkin, “DNA
methyltransferase 1 is essential for and uniquely regulates
hematopoietic stem and progenitor cells,” Cell Stem Cell, vol. 5,
no. 4, pp. 442–449, 2009.
[24] F.Thol, F. Damm, A. Lu¨deking et al., “Incidence and prognostic
influence of DNMT3A mutations in acute myeloid leukemia,”
Journal of Clinical Oncology, vol. 29, no. 21, pp. 2889–2896, 2011.
[25] A. Renneville, N. Boissel, O. Nibourel et al., “Prognostic
significance of DNAmethyltransferase 3Amutations in cytoge-
netically normal acute myeloid leukemia: a study by the Acute
Leukemia French Association,” Leukemia, vol. 26, no. 6, pp.
1247–1254, 2012.
[26] G. Marcucci, K. H. Metzeler, S. Schwind et al., “Age-related
prognostic impact of different types of DNMT3A mutations
in adults with primary cytogenetically normal acute myeloid
leukemia,” Journal of Clinical Oncology, vol. 30, no. 7, pp. 742–
750, 2012.
[27] J. Markova, P. Michkova, K. Burckova et al., “Prognostic impact
of DNMT3A mutations in patients with intermediate cytoge-
netic risk profile acute myeloid leukemia,” European Journal of
Haematology, vol. 88, no. 2, pp. 128–135, 2012.
[28] Y. Shen, Y. M. Zhu, X. Fan et al., “Gene mutation patterns and
their prognostic impact in a cohort of 1185 patients with acute
myeloid leukemia,” Blood, vol. 118, no. 20, pp. 5593–5603, 2011.
[29] H.-A. Hou, Y.-Y. Kuo, C.-Y. Liu et al., “DNMT3A mutations in
acute myeloid leukemia: stability during disease evolution and
clinical implications,” Blood, vol. 119, no. 2, pp. 559–568, 2012.
BioMed Research International 11
[30] Y. Wang, L. Y. Geer, C. Chappey, J. A. Kans, and S. H. Bryant,
“Cn3D: sequence and structure views for Entrez,” Trends in
Biochemical Sciences, vol. 25, no. 6, pp. 300–302, 2000.
[31] M. S. Kim, Y. R. Kim, N. J. Yoo, and S. H. Lee, “Mutational
analysis of DNMT3A gene in acute leukemias and common
solid cancers,” APMIS, vol. 121, no. 2, pp. 85–94, 2013.
